OCM
ACRS icon

Ovata Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Ovata Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,000
Closed -$121K – 22
2023
Q1 		$121K Buy
+15,000
New +$190K 0.05% 29

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ovata Capital Management's ACRS Position: Q2 2023 in Review

Ovata Capital Management sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 15,000 shares — an estimated $121K sold.

Ovata Capital Management first reported a position in ACRS in Q1 2023 and held it in 1 quarter. The position peaked at $121K in Q1 2023. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • Ovata Capital Management reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ovata Capital Management sold 15,000 Aclaris Therapeutics shares in Q2 2023, an estimated $121K.
  • Ovata Capital Management first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 1 quarter.
  • Ovata Capital Management's Aclaris Therapeutics position peaked at $121K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on Ovata Capital Management's 13F filing for Q2 2023, filed 4 Aug 2023.